IMMUNOLOGICAL DETERMINATION OF CHEMOKINE'S ASSOCIATED WITH ISCHEMIC HEART DISEASE
Main Article Content
Keywords
Ischemic heart disease IHD, atherosclerosis, Chemokine's, CCL2, CCL5, CXCL9
Abstract
The aim of present study is to shed the light on the impact chemokine's CCL2, CCL5 and CXCL9 serum level associated with ischemic heart disease IHD of susceptibility and development. The patients were divided according to the clinical condition into three types (stable angina pectoris SAP, unstable angina pectoris UAP, and MI). Which was diagnosed by cardiologists and blood vessels. In this study, the chemokine's were included : measurement of (CCL2, CCL5 and CXCL9) by ELISA. in present study showed that that the mean of serum levels of all chemokine's (pg\ml) among ischemic heart disease IHD patients was higher than control group: where CCL2 was have [ (135, 56 + 51.48) and (18, 28 + 17, 24) ] respectively, CCL5 was have [ (19.77 + 5.81) and (5.93 + 1.70) ] respectively, and CXCL9 that have [ (268.354 + 249.981) and (25.554 + 19.294) ] respectively. statistically the differences was highly significant between IHD and control group that have (P-value 0.001) for all chemokine's study. In present study, when classifying patients group with ischemic heart disease into three types (SAP, UAP and MI), it was noted that the mean levels of CCL2 chemokine in the serum were uneven between the three types, as they were CCL2 serum level is higher at SAP than UAP and MI, compared with the control group. statistically the differences was very highly significant for SAP and significant with UAP and no significant with MI that have [(P-value 0.001), (P-value 0.011) and (P-value 0.302)] respectively. In this study, it was noted that the mean levels of CCL5 chemokine in UAP was slightly high than SAP and MI but, all the results showed an increase in CCL5 serum levels when compared with the control group. statistically the differences was very highly significant for SAP and and no significant with UAP and MI that have [(P-value 0.001), (P-value 0.236) and (P-value 0.103)] respectively. While regarded CXCL9 chemokine, this study noted the mean levels of CXCL9 chemokine in serum of MI was slightly high than SAP and high than USP but, all the results showed an increase of CXCL9 serum levels when compared with the control group. statistically the differences was very highly significant for SAP and and no significant with UAP and MI that have [(P-value 0.001), (P-value 0.494) and (P-value 0.279) ] respectively. In this present study, when samples were taken from the vein and artery of patient with IHD, and comparison the results between them. It was found that the mean level of chemokine (CCL2, CCL5 and CXCL9) in artery sample was higher than mean level of vein sample. statistically [(P-value 0.016), (P-value 0.005) and (P-value 0.0.262)] respectively.
References
2. Benjamin EJ, Virani SS, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL KT. (2020), Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease High Blood Cholesterol and Other Lipids. 2020. p. 9–11.
3. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL KT. (2020), Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease High Blood Cholesterol and Other Lipids. 2020. p. 9–11.
4. Buchari ·(2018). World health statistics 2018.
5. Sampasa - Kanyinga H, Lewis RF (2015). Frequent use of social networking sites is associated with poor psychological functioning among children and adolescents. Cyberpsychology Behav Soc Netw . 2015, 18: 380 385. 10.1089 / cyber.2015.0055.
6. Szentes V, Gazdag M, Szokodi I and Dézsi CA (2018) The Role of CXCR3 and Associated Chemokines in the Development of Atherosclerosis and During Myocardial Infarction. Front. Immunol. 9:1932.
7. Mamazhakypov, Argen; Viswanathan, Gayathri; Lawrie, Allan; Schermuly, Ralph T.; Rajagopal, Sudarshan (2019). The role of chemokines and chemokine receptors in pulmonary arterial hypertension. British Journal of Pharmacology, (), bph.14826–. doi:10.1111/bph.14826.
8. Márquez, A.B.; van der Vorst, E.P.C.; Maas, S.L. (2021), Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential. J. Clin. Med. 2021, 10, 3825.
9. Lu X, Wang Z, Ye D, Feng Y, Liu M, Xu Y, Wang M, Zhang J, Liu J, Zhao M, Xu S, Ye J and Wan J (2021). The Role of CXC Chemokines in Cardiovascular Diseases. Front. Pharmacol. 12:765768. doi: 10.3389/fphar.2021.765768.
10. Noels, H.; Weber, C.; Koenen, R.R. (2019) Chemokines as therapeutic targets in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 583–592.
11. Deshmane, S.L.; Kremlev, S.; Amini, S.; Sawaya, B.E.(2009). Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon Cytokine Res. 2009, 29, 313–326.
12. Liu, Dan; Zhang, Xiao-lin; Yan, Cheng-hui; Li, Yi; Tian, Xiao-xiang; Zhu, Nan; Rong, Jing-jing; Peng, Cheng-fen; Han, Ya-ling (2015). MicroRNA-495 regulates the proliferation and apoptosis of human umbilical vein endothelial cells by targeting chemokine CCL2. Thrombosis Research, 135(1), 146–154.
13. Gencer, S.; Evans, B.R., van der Vorst, E.P.C.; Döring, Y.; Weber, C. (2021) . Inflammatory Chemokines in Atherosclerosis. Cells 2021, 10, 226.
14. Andersen, T., Ueland, T., Ghukasyan Lakic, T., Åkerblom, A., Bertilsson, M., Aukrust, P., et al. (2019). C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arterioscler Thromb. Vasc. Biol. 39-49.
15. Herder C, Baumert J, Thorand B, (2006). Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol;26:2147–52.
16. serrano-Martinez, M. (2003). Monocyte Chemoattractant Protein-1 Concentration in Coronary Sinus Blood and Severity of Coronary Disease. Circulation, 108(10), 75e–75.
17. Koper-Lenkiewicz, Olga M.; Kamińska, Joanna; Lisowska, Anna; Milewska, Anna; Hirnle, Tomasz; Dymicka-Piekarska, Violetta (2019). Factors Associated with RANTES Concentration in Cardiovascular Disease Patients. BioMed Research International, 2019(), 1–11..
18. De-Lemos JA, Morrow DA, Sabatine MS, et al. (2003). Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690 – 695
19. Arakelyan, J. Petrkova, Z. Hermanova., (2005) ―Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction, ‖ Mediators of Inflammation, vol. 2005, no. 3, pp. 175–179,
20. Murakami, Y., Kurosaki, K., Matsui, K. (2003), Serum MCP-1 and VEGF Levels are not Affected by Inhibition of the Renin-Angiotensin System in Patients with Acute Myocardial Infarction. Cardiovasc Drugs Ther 17, 249–255
21. Economou, E., Tousoulis, D., Katinioti, A., Stefanadis, C., Trikas, A., Pitsavos, C., Tentolouris, C., Toutouza, M. G., & Toutouzas, P. (2001). Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. International journal of cardiology, 80(1), 55–60.
22. Lacolley P, Challande P, Regnault V, Lakattac EG, Wang M. ( 2015), Cellular and molecular determinants of arterial aging. In: Nilsson P, Olsen M, Laurent S, editors. Early Vascular Aging. Academic Press, Elsevier (2015). p. 7-13.
23. Appay V, Rowland-Jones SL (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22: 83–87.
24. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, (2001) RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772–1777.
25. Marques, R.E.; Guabiraba, R.; Russo, R.C.; Teixeira, M.M. (2013) .Targeting CCL5 in inflammation. Expert Opin. Ther. Targets, 17, 1439-1460.
26. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (February 2018). "CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - Reviews. 63: 40–47.
27. Metzemackers, M., Vanheule, V., Janssens, R., Struyf, S., and Proost, P. (2017). Overview of the Mechanisms that May Contribute to the Non-redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. Front. Immunol. 8, 1970.
28. Schall TJ (1991) Biology of the RANTES/SIS cytokine family. Cytokine 3:165–183.
29. Skurk T, Mack I, Kempf K, Kolb H, Hauner H, (2009) Expression andsecretion of RANTES (CCL5) in human adipocytes in response to immunological stimuli and hypoxia. Horm Metab Res 41: 183–189.
30. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR. (2008) CCchemokine and chemokine receptor profiles in visceral and subcutaneousadipose tissue are altered in human obesity. J Clin Endocrinol Metab 93:3215–3221.
31. Herder C, Haastert B, Mu¨ ller-Scholze S, Koenig W, Thorand B, .(2005( Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 54 Suppl 2:S11–S17.
32. Virani, V. Nambi, R. Hoogeveen et al., (2011), ―Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study, ‖ European Heart Journal, vol. 32, no. 4, pp.459–468, 2011.
33. S. J. Koh, J. Y. Kim, Y. J. Hyun et al., (2009)―Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects, ‖ International Journal of Cardiology, vol. 132, no. 1, pp. 102–108.
34. Canouï-Poitrine, F., Luc, G., Mallat, Z., Machez, E., Bingham, A., Ferrieres, J., Ruidavets, J. B., Montaye, M., Yarnell, J., Haas, B., Arveiler, D., Morange, P., Kee, F., Evans, A., Amouyel, P., Ducimetiere, P., Empana, J. P., & PRIME (2011). Study Group Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology, 77(12), 1165–1173.
35. Nomura, Shosaku; Uehata, Shigeru; Saito, Sonoko; Osumi, Kazuoki; Ozeki, Yasushi; Kimura, Yukio (2003). Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thrombosis and Haemostasis, 89(3), 506–512.
36. Cavusoglu, E.; Eng, C.; Chopra, V.; Clark, L. T.; Pinsky, D. J.; Marmur, J. D. (2007). Low Plasma RANTES Levels Are an Independent Predictor of Cardiac Mortality in Patients Referred for Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(4), 929–935.
37. Salim S. Virani, Vijay Nambi, Ron Hoogeveen, Bruce A. Wasserman, Josef Coresh, Franklyn Gonzalez, II, Lloyd E. Chambless, Thomas H. Mosley, Eric Boerwinkle, Christie M. Ballantyne, (2011), Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study, European Heart Journal, Volume 32, Issue 4, February 2011, Pages 459–468,
38. Baer PC, Gauer S, Wegner B, Schubert R, Geiger H.(2006), C-reactive protein induced activation of MAP-K and RANTES in human renal distal tubular epithelial cells in vitro. Clin Nephrol 2006;66:177–183.
39. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (February 2018). "CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - Reviews. 63: 40–47.
40. Hardison J.L., Wrightsman R.A., Carpenter P.M., Lane T.E., Manning J.E. (2006). The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi. Infection and Immunity.;74:125.
41. Lu X, Wang Z, Ye D, Feng Y, Liu M, Xu Y, Wang M, Zhang J, Liu J, Zhao M, Xu S, Ye J and Wan J (2022) The Role of CXC Chemokines in Cardiovascular Diseases. Front. Pharmacol. 12:765768.
42. de Oliviera RTD, Mamoni RL, Souza JR, Fernandes JL, Rios FJ, Gidlund M, et al. (2009) Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease. Int J Cardiol. 136:17–26. doi: 10.1016/j.ijcard.2008.04.009.
43. Andersen, T., Ueland, T., Ghukasyan Lakic, T., Åkerblom, A., Bertilsson, M., Aukrust, P., et al. (2019). C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arterioscler Thromb. Vasc. Biol. 39-49.
44. Zernecke A, Shagdarsuren E, Weber C. (2008) Chemokines in atherosclerosis. an update. Arterioscler Thromb Vasc Biol. 28:1897–908.
45. Szentes V, Gazdag M, Szokodi I and Dézsi CA (2018) The Role of CXCR3 and Associated Chemokines in the Development of Atherosclerosis and During Myocardial Infarction. Front. Immunol. 9:1932.
46. Fernandes JL, Mamoni RL, Orford JL, Garcia C, Selwyn AP, Coelho OR, et al. (2004), Increased Th1 activity in patients with coronary artery disease. Cytokine (2004) 26:131-7.
47. Segers D, Lipton JA, Leenen PJ, Cheng C, Tempel D, Pasterkamp G, et al.(2011) Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. Int J Inflam. (2011) 2011:936109.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Ibrahim R. Aljboury
Imam Al-Sadiq Hospital and Babylon Center for Catheterization and Cardiac Surgery, Babil, IRAQ
Haider Abdul-Lateef Mousa
Dept. Microbiology, College of Medicine, University of Basrah, Basrah, IRAQ
Ihsan E. Alsaimary
Department of microbiology collage of medicine university of Basrah